...
search icon
olma-img

Olema Pharmaceuticals Inc, Common Stock

OLMA

NSQ

$5.04

-$0.12

(-2.33%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$322.26M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
519.22K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.04
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.86 L
$16.62 H
$5.04

About Olema Pharmaceuticals Inc, Common Stock

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameOLMASectorS&P500
1-Week Return7.01%-1.91%-1.87%
1-Month Return0.6%-3.82%8.93%
3-Month Return4.56%-11.56%-2.39%
6-Month Return-43.43%-10.21%-2.41%
1-Year Return-42.27%-9.91%10.88%
3-Year Return112.66%-0.28%46.93%
5-Year Return-89.71%31.29%94.89%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue11.00K1.66M1.66M377.00K393.00K[{"date":"2020-12-31","value":0.66,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.7,"profit":true},{"date":"2023-12-31","value":22.67,"profit":true},{"date":"2024-12-31","value":23.63,"profit":true}]
Gross Profit(11.00K)(1.66M)(1.66M)(377.00K)-[{"date":"2020-12-31","value":-1100000,"profit":false},{"date":"2021-12-31","value":-166300000,"profit":false},{"date":"2022-12-31","value":-165800000,"profit":false},{"date":"2023-12-31","value":-37700000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)-[{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses21.53M71.49M106.99M104.58M142.26M[{"date":"2020-12-31","value":15.13,"profit":true},{"date":"2021-12-31","value":50.25,"profit":true},{"date":"2022-12-31","value":75.21,"profit":true},{"date":"2023-12-31","value":73.52,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(21.53M)(71.49M)(106.99M)(104.96M)(142.26M)[{"date":"2020-12-31","value":-2152800000,"profit":false},{"date":"2021-12-31","value":-7149100000,"profit":false},{"date":"2022-12-31","value":-10698800000,"profit":false},{"date":"2023-12-31","value":-10496100000,"profit":false},{"date":"2024-12-31","value":-14225800000,"profit":false}]
Total Non-Operating Income/Expense(1.19M)837.00K4.43M14.05M25.47M[{"date":"2020-12-31","value":-4.66,"profit":false},{"date":"2021-12-31","value":3.29,"profit":true},{"date":"2022-12-31","value":17.39,"profit":true},{"date":"2023-12-31","value":55.18,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(22.12M)(71.10M)(104.79M)(96.66M)(129.47M)[{"date":"2020-12-31","value":-2212100000,"profit":false},{"date":"2021-12-31","value":-7109600000,"profit":false},{"date":"2022-12-31","value":-10478700000,"profit":false},{"date":"2023-12-31","value":-9665500000,"profit":false},{"date":"2024-12-31","value":-12947400000,"profit":false}]
Income Taxes642.00K(210.00K)(2.20M)-(1.00)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-32.71,"profit":false},{"date":"2022-12-31","value":-342.83,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(22.76M)(70.89M)(102.59M)-(129.47M)[{"date":"2020-12-31","value":-2276300000,"profit":false},{"date":"2021-12-31","value":-7088600000,"profit":false},{"date":"2022-12-31","value":-10258600000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-12947399900,"profit":false}]
Income From Continuous Operations(22.12M)(71.10M)(104.79M)(96.06M)(129.47M)[{"date":"2020-12-31","value":-2212100000,"profit":false},{"date":"2021-12-31","value":-7109600000,"profit":false},{"date":"2022-12-31","value":-10478700000,"profit":false},{"date":"2023-12-31","value":-9606200000,"profit":false},{"date":"2024-12-31","value":-12947400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(22.76M)(70.89M)(102.59M)(96.66M)(129.47M)[{"date":"2020-12-31","value":-2276300000,"profit":false},{"date":"2021-12-31","value":-7088600000,"profit":false},{"date":"2022-12-31","value":-10258600000,"profit":false},{"date":"2023-12-31","value":-9665500000,"profit":false},{"date":"2024-12-31","value":-12947400000,"profit":false}]
EPS (Diluted)(0.53)(1.80)(2.62)(2.16)(2.21)[{"date":"2020-12-31","value":-53,"profit":false},{"date":"2021-12-31","value":-180,"profit":false},{"date":"2022-12-31","value":-262,"profit":false},{"date":"2023-12-31","value":-216,"profit":false},{"date":"2024-12-31","value":-221,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

OLMA
Cash Ratio 15.07
Current Ratio 15.22

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

OLMA
ROA (LTM) -27.44%
ROE (LTM) -41.59%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

OLMA
Debt Ratio Lower is generally better. Negative is bad. 0.06
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.94

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

OLMA
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.90
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Olema Pharmaceuticals Inc share price today?

Olema Pharmaceuticals Inc (OLMA) share price today is $5.04

Can Indians buy Olema Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Olema Pharmaceuticals Inc (OLMA) on Vested. To buy Olema Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in OLMA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Olema Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Olema Pharmaceuticals Inc (OLMA) via the Vested app. You can start investing in Olema Pharmaceuticals Inc (OLMA) with a minimum investment of $1.

How to invest in Olema Pharmaceuticals Inc shares from India?

You can invest in shares of Olema Pharmaceuticals Inc (OLMA) via Vested in three simple steps:

  • Click on Sign Up or Invest in OLMA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Olema Pharmaceuticals Inc shares
What is Olema Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Olema Pharmaceuticals Inc (OLMA) is $16.62. The 52-week low price of Olema Pharmaceuticals Inc (OLMA) is $2.86.

What is Olema Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Olema Pharmaceuticals Inc (OLMA) is 0.90

What is the Market Cap of Olema Pharmaceuticals Inc?

The market capitalization of Olema Pharmaceuticals Inc (OLMA) is $322.26M

What is Olema Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Olema Pharmaceuticals Inc is OLMA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top